Losartan Potassium & HCTZ Tablets 50mg/12.5 mg, hydrochlorothiazide USP 12.5, Pkg Size: 90, NDC: 68788-7758-09.

Recall Insight

This FDA Drug action (record #D-0891-2022) was formally reported on June 1, 2022, with the manufacturer initiating the action on May 3, 2022. It is classified under Moderate severity (Class II), with a current status of Terminated. Preferred Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Anaheim, CA. Federal records indicate 31 bottles of 90 tables (Lot: K1721D); 5 bottles of 90 tablets (K1021E). units are affected, placing this recall in the million-unit bracket that typically triggers nationwide consumer alerts and retailer sweeps.

The documented reason for this recall is: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits Distribution data in the federal record shows the product reached: Within the U.S in FL and CA.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls, of which 5 were also issued by FDA Drug. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 4 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.